Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein A-I (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Methods
DNA Analyses
2.3. Statistical Analyses
3. Results
3.1. Intersexual Variability in the Activity of PON1, the Concentration of Lipid Profile Parameters and Selected Markers of Oxidative Stress
3.2. Results of Genotyping
3.3. Alteration in the Activity of PON1, the Concentration of Lipid Profile Parameters and Selected Markers of Oxidative Stress in Terms of Genotypes for SNP rs662 in the PON1 Gene
3.4. Alteration in the Activity of PON1, the Concentration of Lipid Profile Parameters and Selected Markers of Oxidative Stress in Terms of Genotypes for SNP −75 bp in the APOA1 Gene
3.5. Alteration in the Activity of PON1, the Concentration of Lipid Profile Parameters and Selected Markers of Oxidative Stress in Terms of Genotypes for SNP +83 bp in the APOA1 Gene
3.6. The Results for the Odds Ratio Analysis and the Correlation Coefficients
4. Discussion
5. Summary
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Pădureanu, V.; Florescu, D.; Pădureanu, R.; Ghenea, A.; Gheonea, D.; Oancea, C. Role of antioxidants and oxidative stress in the evolution of acute pancreatitis (Review). Exp. Ther. Med. 2022, 23, 197. [Google Scholar] [CrossRef]
- Iannuzzi, J.P.; King, J.A.; Leong, J.H.; Quan, J.; Windsor, J.W.; Tanyingoh, D.; Coward, S.; Forbes, N.; Heitman, S.J.; Shaheen, A.-A.; et al. Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis. Gastroenterology 2022, 162, 122–134. [Google Scholar] [CrossRef]
- Zhang, Y.; Guo, F.; Li, S.; Wang, F.; Meng, Z.; Zhao, J.; Liu, Z.; Wang, B.; Fan, P.; Wang, C.; et al. Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis. Sci. Rep. 2017, 7, 8064. [Google Scholar] [CrossRef] [Green Version]
- Zakrzewska-Pniewska, B.; Nojszewska, M.; Róg, T.; Pniewski, J.; Dorobek, M.; Styczyńska, M.; Szczudlik, A. Polymorphisms of paraoxonase 1 and 2 genes and the risk of multiple sclerosis in the Polish population. Neurol. I Neurochir. Pol. 2013, 47, 49–52. [Google Scholar] [CrossRef]
- Salih, R.K.M.; Hasan, N.A.; Hashim, R.B. The impact of rs662 genotyping on the serum activity of the paraoxonase -1 enzyme in iraqi patients with cardiovascular diseases. IJAR 2017, 5, 825–835. [Google Scholar] [CrossRef] [Green Version]
- Wysocka, A.; Cybulski, M.; Wysokiński, A.P.; Berbeć, H.; Stążka, J.; Zapolski, T. Paraoxonase 1 Activity, Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery. J. Clin. Med. 2019, 8, 441. [Google Scholar] [CrossRef] [Green Version]
- Alharbi, K.K.; Alnbaheen, M.S.; Alharbi, F.K.; Hasanato, R.M.; Khan, I.A. Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population. Ann. Saudi Med. 2017, 37, 425–432. [Google Scholar] [CrossRef] [Green Version]
- Säemann, M.D.; Poglitsch, M.; Kopecky, C.; Haidinger, M.; Hörl, W.H.; Weichhart, T. The versatility of HDL: A crucial anti-inflammatory regulator: THE VERSATILITY OF HDL. Eur. J. Clin. Investig. 2010, 40, 1131–1143. [Google Scholar] [CrossRef]
- Márquez, A.B.; Nazir, S.; van der Vorst, E.P.C. High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression? Biomedicines 2020, 8, 549. [Google Scholar] [CrossRef]
- Menini, T.; Gugliucci, A. Paraoxonase 1 in neurological disorders. Redox Rep. 2014, 19, 49–58. [Google Scholar] [CrossRef] [Green Version]
- Hosseini-Esfahani, F.; Mirmiran, P.; Daneshpour, M.S.; Mottaghi, A.; Azizi, F. The Effect of Interactions of Single Nucleotide Polymorphisms of APOA1/APOC3 with Food Group Intakes on the Risk of Metabolic Syndrome. Avicenna J. Med. Biotechnol. 2017, 9, 94–103. [Google Scholar] [PubMed]
- Georgila, K.; Vyrla, D.; Drakos, E. Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. Cancers 2019, 11, 1097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Litvinov, D.; Mahini, H.; Garelnabi, M. Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases. N. Am. J. Med. Sci. 2012, 4, 523–532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feng, D.W.; Ma, R.L.; Guo, H.; He, J.; Yan, Y.Z.; Muratbek, M.; Niu, Q.; Li, S.G.; Rui, D.S.; Sun, F.; et al. Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang. Genet. Mol. Res. 2016, 15, 1–8. [Google Scholar] [CrossRef]
- Ma, Y.Q.; Thomas, G.N.; Tomlinson, B. Association of two apolipoprotein A-I gene MspI polymorphisms with lipid and blood pressure levels. Int. J. Cardiol. 2005, 102, 309–314. [Google Scholar] [CrossRef] [Green Version]
- Marek, G.; Ściskalska, M.; Grzebieniak, Z.; Milnerowicz, H. Decreases in Paraoxonase-1 Activities Promote a Pro-inflammatory Effect of Lipids Peroxidation Products in Non-smoking and Smoking Patients with Acute Pancreatitis. Int. J. Med. Sci. 2018, 15, 1619–1630. [Google Scholar] [CrossRef] [Green Version]
- Ściskalska, M.; Ołdakowska, M.; Marek, G.; Milnerowicz, H. Increased risk of acute pancreatitis occurrence in smokers with rs5751901 polymorphisms in GGT1 gene. Int. J. Med. Sci. 2020, 17, 242–254. [Google Scholar] [CrossRef] [Green Version]
- Ściskalska, M.; Milnerowicz, H. Association of genetic variants in the GPX1 and GPX4 genes with the activities of glutathione-dependent enzymes, their interaction with smoking and the risk of acute pancreatitis. Biomed. Pharmacother. 2022, 146, 112591. [Google Scholar] [CrossRef]
- Ściskalska, M.; Milnerowicz, H. Activity of glutathione S-transferase and its π isoenzyme in the context of single nucleotide polymorphism in the GSTP1 gene (rs1695) and tobacco smoke exposure in the patients with acute pancreatitis and healthy subjects. Biomed. Pharmacother. 2021, 140, 111589. [Google Scholar] [CrossRef]
- Tisato, V.; Romani, A.; Tavanti, E.; Melloni, E.; Milani, D.; Bonaccorsi, G.; Sanz, J.M.; Gemmati, D.; Passaro, A.; Cervellati, C. Crosstalk Between Adipokines and Paraoxonase 1: A New Potential Axis Linking Oxidative Stress and Inflammation. Antioxidants 2019, 8, 287. [Google Scholar] [CrossRef]
- Wang, X.L.; Liu, S.X.; McCredie, R.M.; Wilcken, D.E. Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J. Clin. Investig. 1996, 98, 372–377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gaidukov, L.; Viji, R.I.; Yacobson, S.; Rosenblat, M.; Aviram, M.; Tawfik, D.S. ApoE Induces Serum Paraoxonase PON1 Activity and Stability Similar to ApoA-I. Biochemistry 2010, 49, 532–538. [Google Scholar] [CrossRef] [PubMed]
- Teimouri, M.; Nayeri, H. Association of serum paraoxonase activity with lipid profile, APO-A and APO-B in subjects with different levels of HDL. Artres 2018, 24, 32. [Google Scholar] [CrossRef]
- Tang, W.; Liu, J.; Wang, Y.; Chen, Y.; Kang, M.; Yin, J.; Liu, C.; Lin, J.; Chen, Y. Association between Paraoxonase 1 polymorphisms and risk of esophagogastric junction adenocarcinoma: A case-control study involving 2,740 subjects. Oncotarget 2017, 8, 101095–101102. [Google Scholar] [CrossRef] [Green Version]
- Scherrer, D.Z.; de Souza Zago, V.H.; Vieira, I.C.; Parra, E.S.; Panzoldo, N.B.; Alexandre, F.; Secolin, R.; Baracat, J.; Quintão, E.C.R.; de Faria, E.C. p.Q192R SNP of PON1 seems not to be Associated with Carotid Atherosclerosis Risk Factors in an Asymptomatic and Normolipidemic Brazilian Population Sample. Arq. Bras. Cardiol. 2015, 105, 45–52. [Google Scholar] [CrossRef]
- Loued, S.; Isabelle, M.; Berrougui, H.; Khalil, A. The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Life Sci. 2012, 90, 82–88. [Google Scholar] [CrossRef]
- Medina-Díaz, I.M.; Ponce-Ruíz, N.; Rojas-García, A.E.; Zambrano-Zargoza, J.F.; Bernal-Hernández, Y.Y.; González-Arias, C.A.; Barrón-Vivanco, B.S.; Herrera-Moreno, J.F. The Relationship between Cancer and Paraoxonase 1. Antioxidants 2022, 11, 697. [Google Scholar] [CrossRef]
- Zhou, C.; Cao, J.; Shang, L.; Tong, C.; Hu, H.; Wang, H.; Fan, D.; Yu, H. Reduced Paraoxonase 1 Activity as a Marker for Severe Coronary Artery Disease. Dis. Markers 2013, 35, 97–103. [Google Scholar] [CrossRef] [Green Version]
- Ben-David, M.; Elias, M.; Filippi, J.-J.; Duñach, E.; Silman, I.; Sussman, J.L.; Tawfik, D.S. Catalytic Versatility and Backups in Enzyme Active Sites: The Case of Serum Paraoxonase 1. J. Mol. Biol. 2012, 418, 181–196. [Google Scholar] [CrossRef]
- Sadr-Azodi, O.; Andrén-Sandberg, Å.; Orsini, N.; Wolk, A. Cigarette smoking, smoking cessation and acute pancreatitis: A prospective population-based study. Gut 2012, 61, 262–267. [Google Scholar] [CrossRef]
- Haj Mouhamed, D.; Ezzaher, A.; Mechri, A.; Neffati, F.; Omezzine, A.; Bouslama, A.; Gaha, L.; Douki, W.; Najjar, M.F. Effect of cigarette smoking on paraoxonase 1 activity according to PON1 L55M and PON1 Q192R gene polymorphisms. Environ. Health Prev. Med. 2012, 17, 316–321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; He, J.; Guo, H.; Mu, L.; Hu, Y.; Ma, J.; Yan, Y.; Ma, R.; Li, S.; Ding, Y.; et al. Interactions of six SNPs in APOA1 gene and types of obesity on low HDL-C disease in Xinjiang pastoral area of China. Lipids Health Dis. 2017, 16, 187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pakdel, A.; Akbari Eidgahi, M.R.; Bandegi, A.R. Association Between MspI Polymorphisms of the Apolipoprotein A-I Gene and Hyperlipidemia in an Iranian Population. Middle East J. Rehabil. Health Stud. 2018, 5, e60496. [Google Scholar] [CrossRef] [Green Version]
- Dixit, M.; Choudhuri, G.; Saxena, R.; Mittal, B. Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease. Can. J. Gastroenterol. 2007, 21, 569–575. [Google Scholar] [CrossRef] [Green Version]
- Grdic Rajkovic, M.; Rumora, L.; Barisic, K. The paraoxonase 1, 2 and 3 in humans. Biochem. Med. 2011, 21, 122–130. [Google Scholar] [CrossRef]
- Corsetti, J.P.; Sparks, C.E.; James, R.W.; Bakker, S.J.L.; Dullaart, R.P.F. Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein. J. Clin. Med. 2019, 8, 1357. [Google Scholar] [CrossRef] [Green Version]
- Domínguez-Díaz, C.; Morán-Moguel, M.C.; Navarro-Hernandez, R.E.; Romo-Vázquez, R.; Mendizabal-Ruiz, A.P. Association of SNP rs5069 in APOA1 with Benign Breast Diseases in a Mexican Population. Genes 2022, 13, 738. [Google Scholar] [CrossRef]
- Liao, B.; Cheng, K.; Dong, S.; Liu, H.; Xu, Z. Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease. Diagn. Pathol. 2015, 10, 102. [Google Scholar] [CrossRef] [Green Version]
- Hamrita, B.; Nasr, H.B.; Gabbouj, S.; Bouaouina, N.; Chouchane, L.; Chahed, K. Apolipoprotein A1 −75 G/A and +83 C/T polymorphisms: Susceptibility and prognostic implications in breast cancer. Mol. Biol. Rep. 2011, 38, 1637–1643. [Google Scholar] [CrossRef]
- Kumaraswamy, S.B.; Linder, A.; Akesson, P.; Dahlback, B. Decreased Plasma Concentrations of Apolipoprotein M in Sepsis and Systemic Inflammatory Response Syndromes. Crit. Care 2012, 16, R60. [Google Scholar] [CrossRef]
- Meisinger, C.; Freuer, D.; Bub, A.; Linseisen, J. Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: A cross-sectional study. Lipids Health Dis. 2021, 20, 81. [Google Scholar] [CrossRef] [PubMed]
- Kahraman, F.U.; Torun, E.; Osmanoğlu, N.K.; Oruçlu, S.; Özer, Ö.F. Serum oxidative stress parameters and paraoxonase-1 in children and adolescents exposed to passive smoking. Pediatr. Int. 2017, 59, 68–73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wroblewski, J.M.; Jahangiri, A.; Ji, A.; de Beer, F.C.; van der Westhuyzen, D.R.; Webb, N.R. Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J. Lipid Res. 2011, 52, 2255–2261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, H.; Yu, B.; Liu, W.; Lin, Q.; Chen, L.; Chen, J.; Duan, L.; Shi, G. Serum apoprotein A1 levels are inversely associated with disease activity in gout: From a southern Chinese Han population. Medicine 2017, 96, e6780. [Google Scholar] [CrossRef]
- Chen, E.S.; Mazzotti, D.R.; Furuya, T.K.; Cendoroglo, M.S.; Ramos, L.R.; Araujo, L.Q.; Burbano, R.R.; de Arruda Cardoso Smith, M. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin. Exp. Med. 2009, 9, 319–325. [Google Scholar] [CrossRef]
Parameters | Mean ± SD | Mean ± SD | |
---|---|---|---|
Healthy Subjects | |||
Non-Smokers (n = 23) | Smokers (n = 28) | p | |
Gender [% female/% male] | 83%/17% | 54%/46% | - |
Age [years] | 45.7 ± 8.7 | 46.1 ± 8.4 | 0.8684 |
BMI [kg/m2] | 22.7 ± 1.6 | 23.0 ± 2.1 | 0.5757 |
hsCRP [mg/L] | 0.6 ± 0.2 | 0.4 ± 0.1 | <0.0001 |
The patients with acute pancreatitis | |||
Non-smokers (n = 17) | Smokers (n = 27) | p | |
Gender [% female/% male] | 53%/47% | 26%/74% | - |
Age [years] | 47.3 ± 15.0 | 48.2 ± 13.3 | 0.8979 |
BMI [kg/m2] | 27.6 ± 5.9 | 24.1 ± 4.3 | 0.1411 |
hsCRP [mg/L] | 112.3 ± 128.3 | 101.9 ± 99.2 | 0.8318 |
Lipase [U/L] | 120.7 ± 98.9 | 213.5 ± 177.0 | 0.2726 |
Amylase [U/L] | 529.1 ± 692.0 | 449.8 ± 732.1 | 0.7601 |
ALT [U/L] | 27.1 ± 20.2 | 30.2 ± 20.6 | 0.7145 |
AST [U/L] | 102.2 ± 173.1 | 71.5 ± 77.3 | 0.5648 |
GGT [U/L] | 227.0 ± 275.0 | 273.6 ± 295.6 | 0.7087 |
Erythrocytes [1012/L] | 4.2 ± 1.0 | 4.4 ± 0.9 | 0.6680 |
Leukocytes [109/L] | 13.1 ± 3.4 | 12.3 ± 4.0 | 0.6379 |
Hemoglobin [g/dL] | 12.6 ± 3.1 | 13.5 ± 2.5 | 0.4443 |
Hematocrit [%] | 36.9 ± 7.7 | 39.8 ± 6.3 | 0.3498 |
Bilirubin (total) [mg/dL] | 1.7 ± 1.6 | 1.8 ± 2.2 | 0.8383 |
Alkaline phosphatase [U/L] | 250.2 ± 317.9 | 157.3 ± 119.7 | 0.3276 |
Urea [mg/dL] | 35.7 ± 34.7 | 31.3 ± 27.2 | 0.7420 |
Creatinine [mg/dL] | 1.6 ± 1.7 | 2.4 ± 5.4 | 0.7076 |
eGFR [mL/min/1.73 m2] | 67.9 ± 30.5 | 91.4 ± 42.3 | 0.2010 |
Total protein [g/dL] | 6.5 ± 0.5 | 6.4 ± 0.6 | 0.9578 |
Total cholesterol [mg/dL] | 158.0 ± 38.2 | 163.0 ± 24.6 | 0.9322 |
Sodium [mmol/L] | 136.6 ± 3.5 | 129.7 ± 28.6 | 0.5088 |
Potassium [mmol/L] | 4.0 ± 0.5 | 4.1 ± 0.6 | 0.7125 |
Cotinine [ng/mL] | 6.8 ± 14.6 | 128.8 ± 58.6 | <0.0001 |
Parameters | Healthy Subjects | p | The Patients with Acute Pancreatitis | p | ||
---|---|---|---|---|---|---|
Women (n = 34) | Men (n = 17) | Women (n = 16) | Men (n = 28) | |||
PON1(P)
activity [U/L] | 265.9 ± 139.4 (147.2; 225.4; 395.9) | 228.7 ± 170.2 (150.6; 179.7; 245.7) | 0.4112 | 68.5 ± 44.1 ** (42.2; 62.5; 79.8) | 85.6 ± 48.8 *** (48.9; 79.0; 48.8) | 0.2871 |
PON1(A) activity [U/L] | 115.0 ± 42.2 (85.8; 113.3; 136.3) | 109.5 ± 48.0 (80.7; 115.3; 145.9) | 0.6760 | 136.7 ± 55.6 (93.2; 142.0; 175.3) | 124.6 ± 63.5 (84.2; 126.9; 63.5) | 0.5392 |
PON1(L) activity [U/L] | 8.5 ± 3.0 (6.3; 8.5; 10.7) | 8.2 ± 4.0 (5.8; 8.6; 10.1) | 0.7727 | 6.3 ± 2.1 ** (5.0; 5.7; 8.7) | 6.3 ± 3.2 (4.2; 5.9; 3.2) | 0.9694 |
PON1 concentration [µg/mL] | 25.2 ± 7.3 (21.0; 26.3; 30.0) | 21.5 ± 5.9 (17.5; 20.7; 26.8) | 0.1413 | 19.1 ± 8.7 (14.6; 16.1; 25.1) | 19.8 ± 11.2 (14.7; 16.9; 11.2) | 0.8657 |
ApoA-I concentration [g/L] | 1.4 ± 0.4 (1.0; 1.3; 1.7) | 1.5 ± 0.4 (1.2; 1.4; 1.6) | 0.3788 | 1.1 ± 0.6 (0.6; 1.0; 1.3) | 0.8 ± 0.5 *** (0.4; 0.7; 0.5) | 0.2893 |
HDL concentration [mg/dL] | 68.8 ± 14.6 (57.5; 69.5; 80.0) | 57.2 ± 11.3 * (49.0; 56.0; 65.0) | 0.0066 | 50.9 ± 21.2 ** (31.6; 52.0; 67.0) | 45.5 ± 19.4 *** (29.1; 44.7; 19.4) | 0.4267 |
TC/HDL ratio | 3.2 ± 1.1 (2.5; 2.8; 3.5) | 3.4 ± 0.5 (3.0; 3.4; 3.8) | 0.3359 | 4.0 ± 2.0 (2.5; 2.7; 6.1) | 4.3 ± 2.3 (2.6; 3.9; 2.3) | 0.7647 |
LDL/HDL ratio | 1.8 ± 0.9 (1.3; 1.6; 2.0) | 2.1 ± 0.5 (1.8; 2.1; 2.4) | 0.3388 | 2.3 ± 1.7 (1.2; 1.4; 3.8) | 2.7 ± 2.1 (1.1; 2.3; 2.1) | 0.5568 |
oxLDL/LDL ratio [U/g] | 54.5 ± 22.2 (39.9; 49.5; 63.7) | 53.1 ± 28.8 (33.2; 54.0; 61.0) | 0.8743 | 71.8 ± 39.1 (50.4; 60.5; 83.2) | 60.2 ± 46.4 (27.9; 36.9; 46.4) | 0.5991 |
Polymorphism | Genotype | Healthy Subjects | AP Patients | OR (95% CI) | p-Value |
---|---|---|---|---|---|
rs662 (PON1) | T/T | 44 (86.3%) | 40 (90.9%) | 1.00 | 0.48 |
T/C | 7 (13.7%) | 4 (9.1%) | 1.59 (0.43–5.84) | ||
rs670 (−75 G/A) (APOA1) | G/G | 32 (62.8%) | 23 (52.3%) | 1.00 | 0.036 |
A/G | 15 (29.4%) | 9 (20.4%) | 1.20 (0.45–3.21) | ||
A/A | 4 (7.8%) | 12 (27.3%) | 0.24 (0.07–0.84) | ||
A/G | 15 | 9 | 1.00 | 0.23 | |
G/G–A/A | 36 | 35 | 0.56 (0.22–1.44) | ||
rs5069 (+83 C/T) (APOA1) | C/C | 44 (86.3%) | 29 (65.9%) | 1.00 | 0.018 |
T/C | 7 (13.7%) | 15 (34.1%) | 0.31 (0.11–0.85) |
Parameters | Genotypes | Healthy Subjects (n = 51) | The Patients with Acute Pancreatitis (n = 44) | ||
---|---|---|---|---|---|
1st Day of Hospitalization | 3rd Day of Hospitalization | 7th Day of Hospitalization | |||
PON1(P)
activity [U/L] | T/T | 214.0 ± 114.3 | 80.7 ± 49.1 * | 85.7 ± 74.5 | 66.2 ± 67.7 |
(144.7; 173.4; 264.9) | (43.4; 71.2; 99.1) | (32.2; 52.0; 137.1) | (24.4; 49.7; 92.8) | ||
T/C | 341.8 ± 160.7 ** | 67.0 ± 28.0 * | 73.5 ± 54.1 | 81.1 ± 64.0 | |
(229.8; 288.9; 472.7) | (44.2; 61.7; 89.8) | (34.6; 62.2; 112.4) | (38.2; 50.4; 154.7) | ||
PON1(A) activity [U/L] | T/T | 111.9 ± 45.5 | 128.9 ± 63.5 | 106.0 ± 55.9 | 93.5 ± 54.5 # |
(81.7; 115.3; 142.8) | (87.6; 135.4; 165.3) | (53.6; 109.2; 143.8) | (49.6; 94.0; 138.3) | ||
T/C | 121.3 ± 33.1 | 124.4 ± 37.2 | 107.1 ± 30.6 | 107.9 ± 46.2 | |
(100.3; 112.7; 145.9) | (96.1; 115.2; 152.8) | (82.3; 103.4; 131.9) | (75.9; 86.9; 160.9) | ||
PON1(L) activity [U/L] | T/T | 8.5 ± 3.4 | 6.4 ± 2.9 * | 5.6 ± 2.6 | 4.9 ± 2.2 # |
(6.1; 8.7; 10.6) | (4.6; 5.8; 8.7) | (3.9; 5.6; 6.9) | (3.2; 4.1; 6.7) | ||
T/C | 7.7 ± 3.1 | 4.7 ± 2.0 * | 4.2 ± 1.7 | 3.8 ± 1.9 | |
(5.5; 6.4; 10.1) | (3.1; 4.3; 6.3) | (2.8; 4.3; 5.6) | (2.6; 2.7; 6.0) | ||
PON1 concentration [µg/mL] | T/T | 23.4 ± 7.1 | 20.3 ± 10.4 | 16.6 ± 8.2 | 14.5 ± 7.4 |
(17.8; 24.6; 28.3) | (14.7; 16.4; 29.2) | (10.5; 13.9; 21.7) | (8.6; 13.5; 21.2) | ||
T/C | 25.3 ± 6.6 | 16.2 ± 6.4 | 10.4 ± 2.7 | 12.0 ± 7.2 | |
(21.6; 25.8; 29.7) | (11.8; 16.8; 20.5) | (8.5; 10.3; 12.3) | (7.2; 8.6; 20.3) | ||
ApoA-I concentration [g/L] | T/T | 1.4 ± 0.4 | 0.9 ± 0.5 * | 0.8 ± 0.6 | 0.7 ± 0.3 |
(1.0; 1.3; 1.6) | (0.6; 0.7; 1.2) | (0.3; 0.4; 1.3) | (0.5; 0.7; 0.7) | ||
T/C | 1.6 ± 0.4 | 1.0 ± 0.8 | 0.6 ± 0.4 | 0.3 ± 0.1 | |
(1.4; 1.6; 1.8) | (0.4; 0.7; 1.6) | (0.3; 0.5; 0.8) | (0.1; 0.4; 0.4) | ||
HDL concentration [mg/dL] | T/T | 64.1 ± 15.1 | 54.0 ± 31.9 * | 38.8 ± 25.8 | 44.9 ± 24.9 |
(52.0; 63.0; 74.0) | (29.7; 47.1; 67.6) | (17.8; 32.1; 56.4) | (25.0; 42.2; 62.8) | ||
T/C | 68.7 ± 10.5 | 46.0 ± 18.7 * | 49.9 ± 24.2 | 48.3 ± 41.0 | |
(59.0; 69.0; 81.0) | (31.5; 46.7; 60.5) | (29.7; 46.5; 70.1) | (21.3; 28.0; 95.6) | ||
TC/HDL ratio | T/T | 3.3 ± 1.0 | 4.5 ± 3.2 * | 6.4 ± 5.8 # | 5.2 ± 2.9 |
(2.7; 3.0; 3.7) | (2.5; 3.7; 6.1) | (2.6; 4.5; 8.8) | (2.8; 5.0; 6.8) | ||
T/C | 2.9 ± 0.6 | 8.0 ± 6.7 | 5.1 ± 3.2 | 4.0 ± 3.7 | |
(2.5; 2.7; 3.7) | (4.3; 5.3; 11.7) | (2.6; 4.7; 7.7) | (1.4; 4.0; 6.6) | ||
LDL/HDL ratio | T/T | 1.9 ± 0.8 | 3.0 ± 3.1 * | 4.4 ± 5.0 | 3.5 ± 2.2 |
(1.4; 1.8; 3.4) | (1.1; 2.2; 4.1) | (1.2; 3.1; 5.8) | (1.6; 3.6; 4.4) | ||
T/C | 1.7 ± 0.5 | 6.5 ± 6.6 | 3.5 ± 2.5 | 6.8 ± 10.8 | |
(1.2; 1.6; 2.3) | (2.9; 3.8; 10.1) | (1.8; 2.7; 5.3) | (0.0; 1.2; 19.3) | ||
oxLDL/LDL ratio [U/g] | T/T | 55.8 ± 26.1 | 67.6 ± 38.8 | 89.9 ± 36.9 | 63.7 ± 30.6 |
(40.4; 53.9; 60.9) | (39.0; 54.2; 86.5) | (69.7; 92.3; 117.8) | (43.0; 68.3; 90.6) | ||
T/C | 44.8 ± 16.5 | 66.8 ± 53.0 | 90.2 ± 47.2 | 84.6 ± 36.4 | |
(31.8; 41.1; 63.2) | (30.4; 51.6; 103.3) | (42.1; 92.1; 136.5) | (46.7; 80.4; 126.3) | ||
MDA concentration [nmol/µL] | T/T | 0.8 ± 0.6 | 2.2 ± 0.5 * | 2.6 ± 0.7 | 2.9 ± 0.9 # |
(0.3; 0.6; 1.1) | (1.9; 2.2; 2.5) | (2.2; 2.5; 2.9) | (2.3; 2.9; 3.4) | ||
T/C | 1.2 ± 0.8 | 2.4 ± 0.6 * | 2.8 ± 0.4 | 3.4 ± 0.2 # | |
(0.3; 1.1; 2.2) | (2.0; 2.4; 2.8) | (2.4; 2.8; 3.1) | (3.2; 3.3; 3.6) |
Parameters | Genotypes | Healthy Subjects (n = 51) | The Patients with Acute Pancreatitis (n = 44) | ||
---|---|---|---|---|---|
1st Day of Hospitalization | 3rd Day of Hospitalization | 7th Day of Hospitalization | |||
PON1(P)
activity [U/L] | G/G | 261.1 ± 158.5 | 69.2 ± 43.2 * | 67.5 ± 59.4 | 44.9 ± 35.5 |
(145.1; 179.7; 389.1) | (42.8; 61.3; 78.8) | (32.3; 48.3; 85.4) | (26.3; 33.3; 52.1) | ||
A/A | 299.5 ± 252.5 | 61.2 ± 37.2 | 52.1 ± 32.7 | 40.8 ± 22.7 | |
(144.2; 163.1; 591.1) | (42.8; 47.2; 89.0) | (31.7; 46.9; 53.2) | (19.4; 38.2; 64.7) | ||
A/G | 229.3 ± 116.0 | 123.1 ± 30.3 | 173.6 ± 39.2 **/*** | 127.2 ± 38.9 **/*** | |
(151.6; 183.3; 267.3) | (101.7; 123.1; 144.5) | (147.3; 155.0; 218.7) | (99.7; 127.2; 154.7) | ||
PON1(A) activity [U/L] | G/G | 108.0 ± 47.1 | 105.9 ± 49.3 | 97.3 ± 52.0 | 92.1 ± 53.5 |
(81.7; 108.2; 139.8) | (61.1; 117.5; 141.7) | (46.2; 104.4; 150.4) | (49.6; 75.9; 138.3) | ||
A/A | 137.6 ± 13.1 | 104.5 ± 75.5 | 100.6 ± 50.8 | 63.8 ± 41.3 | |
(122.6; 144.5; 145.9) | (28.9; 93.2; 134.5) | (51.2; 98.2; 119.8) | (29.3; 61.5; 98.4) | ||
A/G | 119.0 ± 39.6 | 137.1 ± 49.6 | 140.3 ± 3.2 | 138.6 ± 31.6 | |
(90.0; 115.3; 150.6) | (80.8; 156.2; 174.2) | (138.1; 138.8; 144.0) | (116.2; 138.6; 160.9) | ||
PON1(L) activity [U/L] | G/G | 7.9 ± 3.1 | 4.5 ± 2.1 * | 4.2 ± 1.7 | 3.7 ± 1.9 |
(5.8; 8.1; 9.6) | (3.8; 4.5; 5.3) | (3.0; 4.1; 5.7) | (2.5; 3.2; 5.5) | ||
A/A | 10.1 ± 0.7 | 6.0 ± 3.4 * | 5.4 ± 2.9 | 4.7 ± 2.8 | |
(9.4; 10.0; 10.8) | (2.4; 5.4; 7.7) | (2.4; 5.4; 7.7) | (2.9; 3.6; 6.5) | ||
A/G | 9.1 ± 3.9 | 9.1 ± 3.5 *** | 9.3 ± 3.6 **/*** | 6.6 ± 0.8 | |
(6.4; 8.6; 11.0) | (6.8; 7.4; 13.1) | (5.8; 9.3; 12.9) | (6.0; 6.6; 7.1) | ||
PON1 concentration [µg/mL] | G/G | 25.9 ± 6.1 | 15.6 ± 5.5 * | 12.9 ± 5.0 | 11.5 ± 6.4 |
(20.6; 26.3; 30.1) | (14.7; 15.9; 17.3) | (9.8; 12.1; 18.5) | (3.6; 8.6; 22.2) | ||
A/A | 28.7 ± 0.4 | 20.1 ± 13.7 | 10.4 ± 3.3 | 15.9 ± 5.8 | |
(28.4; 28.7; 29.0) | (7.8; 17.7; 34.8) | (7.1; 10.4; 13.7) | (12.1; 15.3; 18.7) | ||
A/G | 18.7 ± 6.6 | 23.3 ± 12.8 | 15.6 ± 8.9 | 11.6 ± 6.3 | |
(15.8; 19.3; 23.8) | (13.2; 23.1; 29.3) | (10.2; 14.8; 22.8) | (7.8; 11.2; 15.1) | ||
ApoA-I concentration [g/L] | G/G | 1.5 ± 0.4 | 0.8 ± 0.5 * | 0.9 ± 0.6 | 0.6 ± 0.2 |
(1.2; 1.4; 1.7) | (0.5; 0.9; 1.3) | (0.5; 0.9; 1.3) | (0.4; 0.6; 0.7) | ||
A/A | 1.5 ± 0.6 | 1.0 ± 0.7 | 0.5 ± 0.4 | 0.4 ± 0.3 | |
(1.0; 1.5; 2.1) | (0.6; 0.7; 1.6) | (0.3; 0.4; 0.8) | (0.2; 0.4; 0.6) | ||
A/G | 1.2 ±0.3 | 1.0 ± 0.8 | 0.9 ± 0.9 | 0.8 ± 0.6 | |
(1.0; 1.3; 1.4) | (0.4; 0.7; 1.9) | (0.4; 0.5; 1.9) | (0.4; 0.8; 1.2) | ||
HDL concentration [mg/dL] | G/G | 62.7 ± 12.8 | 50.3 ± 21.9 * | 47.9 ± 28.3 | 55.9 ± 24.3 |
(53.0; 63.0; 72.0) | (28.3; 52.8; 70.0) | (21.5; 41.2; 74.9) | (39.7; 47.6; 73.9) | ||
A/A | 67.3 ± 23.6 | 41.2 ± 15.1 * | 30.1 ± 25.1 | 30.1 ± 19.5 | |
(49.0; 59.0; 94.0) | (29.2; 41.5; 44.6) | (14.1; 23.6; 32.1) | (16.5; 21.3; 46.3) | ||
A/G | 68.1 ± 16.5 | 39.9 ± 22.7 * | 44.5 ± 20.9 | 64.3 ± 44.3 | |
(54.0; 64.0; 80.5) | (23.6; 30.2; 65.9) | (21.5; 49.6; 62.4) | (32.9; 64.3; 95.6) | ||
TC/HDL ratio | G/G | 3.2 ± 0.8 | 4.4 ± 2.6 | 5.1 ± 3.8 | 4.4 ± 2.4 |
(2.7; 3.0; 3.7) | (2.3; 3.4; 6.7) | (3.2; 4.0; 8.8) | (2.4; 4.1; 6.3) | ||
A/A | 4.2 ± 2.3 | 4.9 ± 2.0 | 8.2 ± 4.7 | 6.7 ± 3.5 | |
(2.7; 3.0; 6.8) | (3.1; 5.4; 6.5) | (3.8; 8.5; 9.1) | (2.8; 7.6; 9.7) | ||
A/G | 3.0 ± 0.7 | 4.0 ± 2.2 | 4.7 ± 3.2 | 3.7 ± 3.3 | |
(1.9; 2.9; 4.4) | (1.5; 5.2; 5.3) | (2.1; 3.7; 8.4) | (1.4; 3.7; 6.0) | ||
LDL/HDL ratio | G/G | 2.0 ± 0.7 | 3.1 ± 2.4 * | 3.3 ± 2.9 | 2.8 ± 2.2 |
(1.4; 1.8; 2.4) | (3.2; 2.2; 5.5) | (1.1; 3.2; 4.1) | (1.3; 2.7; 4.0) | ||
A/A | 2.8 ± 2.1 | 2.8 ± 1.8 | 5.8 ± 4.3 | 7.9 ± 7.8 | |
(1.4; 1.8; 5.2) | (1.2; 2.6; 4.3) | (1.7; 5.8; 7.1) | (3.3; 5.5; 12.5) | ||
A/G | 1.7 ± 0.5 | 2.5 ± 2.1 | 3.1 ± 2.2 | 2.4 ± 1.7 | |
(1.3; 1.8; 2.0) | (0.1; 3.6; 3.8) | (1.9; 1.9; 5.8) | (1.2; 2.4; 3.6) | ||
oxLDL/LDL ratio [U/g] | G/G | 56.5 ± 22.3 | 64.1 ± 48.3 | 153.4 ± 118.2 # | 57.6 ± 35.5 ## |
(40.8; 53.9; 65.8) | (27.9; 50.4; 89.9) | (97.5; 105.2; 136.5) | (34.4; 46.5; 90.6) | ||
A/A | 48.0 ± 22.8 | 43.6 ± 29.9 | 72.2 ± 26.5 | 68.9 ± 24.6 | |
(31.8; 48.0; 64.2) | (22.4; 43.6; 64.7) | (42.1; 82.3; 92.1) | (42.1; 59.7; 81.4) | ||
A/G | 50.4 ± 30.4 | 42.0 ± 25.6 | 52.6 ± 23.3 | 64.5 ± 27.8 | |
(32.3; 46.9; 57.8) | (25.8; 52.0; 69.8) | (35.9; 50.3; 70.2) | (32.6; 62.3; 92.6) | ||
MDA concentration [nmol/µL] | G/G | 0.9 ± 0.6 | 2.2 ± 0.3 */** | 2.6 ± 0.6 | 3.1 ± 1.0 # |
(0.3; 0.7; 1.3) | (2.0; 2.2; 2.4) | (2.2; 2.6; 3.0) | (2.5; 3.0; 3.5) | ||
A/A | 1.0 ± 1.0 | 2.7 ± 0.5 * | 2.7 ± 0.5 | 2.9 ± 0.4 | |
(0.4; 0.5; 2.2) | (2.5; 2.8; 3.0) | (2.5; 2.6; 2.8) | (2.5; 3.2; 3.2) | ||
A/G | 0.7 ± 0.7 | 1.8 ± 0.6 */** | 2.7 ± 0.7 | 2.7 ± 0.9 | |
(0.3; 0.6; 1.0) | (1.4; 1.8; 2.2) | (2.2; 2.7; 3.2) | (2.1; 2.7; 3.3) |
Parameters | Genotypes | Healthy Subjects (n = 51) | The Patients with Acute Pancreatitis (n = 44) | ||
---|---|---|---|---|---|
1st Day of Hospitalization | 3rd Day of Hospitalization | 7th Day of Hospitalization | |||
PON1(P)
activity [U/L] | C/C | 251.0 ± 142.0 | 61.4 ± 29.7 * | 56.9 ± 40.6 | 36.5 ± 16.5 # |
(147.2; 179.9; 389.1) | (42.8; 59.0; 77.8) | (31.8; 45.8; 77.5) | (36.3; 33.3; 50.4) | ||
T/C | 236.1 ± 81.9 | 89.1 ± 47.5 * | 156.1 ± 58.6 ** | 132.2 ± 28.8 ** | |
(178.3; 237.9; 295.6) | (55.1; 90.7; 123.1) | (102.5; 147.3; 218.7) | (99.7; 142.2; 154.7) | ||
PON1(A) activity [U/L] | C/C | 115.5 ± 42.6 | 104.0 ± 57.3 | 97.3 ± 49.3 | 80.1 ± 49.6 |
(83.2; 114.6; 145.2) | (54.2; 108.9; 136.2) | (51.2; 101.3; 128.4) | (36.1; 74.6; 109.8) | ||
T/C | 98.3 ± 52.1 | 137.1 ± 42.4 | 148.1 ± 12.6 ** | 141.3 ± 22.8 ** | |
(85.8; 93.9; 141.2) | (104.6; 146.6; 169.5) | (138.1; 144.0; 162.3) | (116.2; 146.6; 160.9) | ||
PON1(L) activity [U/L] | C/C | 8.7 ± 3.3 | 5.3 ± 3.1 * | 4.9 ± 2.8 | 3.8 ± 2.2 #/## |
(6.4; 8.7; 10.6) | (3.5; 4.5; 6.2) | (3.0; 4.3; 5.8) | (2.6; 3.2; 4.1) | ||
T/C | 6.6 ± 3.4 | 6.3 ± 1.0 | 7.1 ± 1.9 | 6.2 ± 0.8 ** | |
(5.5; 5.8; 10.4) | (5.5; 6.4; 7.1) | (5.8; 6.3; 9.3) | (5.5; 6.0; 7.1) | ||
PON1 concentration [µg/mL] | C/C | 23.7 ± 6.6 | 15.9 ± 7.3 * | 12.3 ± 4.9 # | 10.2 ± 6.0 # |
(18.5; 23.8; 28.3) | (14.7; 15.9; 17.3) | (9.8; 12.1; 14.5) | (6.8; 8.6; 10.5) | ||
T/C | 24.8 ± 11.9 | 24.2 ± 1.3 ** | 12.1 ± 1.6 # | 19.3 ± 1.4 **/# | |
(11.2; 29.8; 33.2) | (23.3; 24.2; 25.1) | (10.9; 12.1; 13.2) | (18.3; 19.3; 20.3) | ||
ApoA-I concentration [g/L] | C/C | 1.4 ± 0.4 | 0.9 ± 0.5 * | 0.7 ± 0.6 | 0.4 ± 0.2 # |
(1.0; 1.3; 1.6) | (0.6; 0.7; 1.2) | (0.3; 0.5; 1.0) | (0.2; 0.4; 0.5) | ||
T/C | 1.4 ± 0.2 | 0.7 ± 0.6 * | 0.4 ± 0.2 | 0.9 ± 0.7 | |
(11.2; 29.8; 33.2) | (0.3; 0.5; 1.0) | (0.3; 0.4; 0.5) | (0.4; 0.7; 1.5) | ||
HDL concentration [mg/dL] | C/C | 64.8 ± 15.1 | 48.1 ± 20.7 * | 42.5 ± 27.9 | 48.8 ± 26.3 |
(52.0; 63.0; 75.0) | (28.8; 45.9; 66.4) | (18.3; 32.1; 64.8) | (26.5; 46.7; 62.8) | ||
T/C | 64.3 ± 10.7 | 39.8 ± 18.6 * | 46.8 ± 22.1 | 56.2 ± 34.3 | |
(56.0; 61.5; 74.0) | (26.9; 34.7; 52.6) | (21.5; 56.6; 62.3) | (32.9; 40.0; 95.6) | ||
TC/HDL ratio | C/C | 3.1 ± 0.7 | 4.2 ± 2.3 * | 5.6 ± 3.5 | 4.9 ± 2.8 |
(2.6; 2.9; 3.7) | (2.3; 3.4; 6.5) | (2.8; 4.4; 8.8) | (2.5; 4.1; 6.7) | ||
T/C | 3.3 ± 0.5 | 5.5 ± 2.6 * | 4.3 ± 3.6 | 4.2 ± 2.5 | |
(2.7; 3.4; 3.7) | (3.8; 5.3; 7.1) | (2.1; 2.3; 8.4) | (1.4; 5.3; 6.0) | ||
LDL/HDL ratio | C/C | 1.8 ± 0.6 | 2.6 ± 2.1 | 4.1 ± 3.4 # | 3.1 ± 2.3 |
(1.4; 1.7; 2.2) | (1.1; 2.0; 3.8) | (1.7; 3.4; 5.9) | (1.4; 2.7; 4.4) | ||
T/C | 2.0 ± 0.4 | 3.6 ± 1.7 * | 2.9 ± 2.5 | 2.8 ± 1.4 | |
(1.6; 2.1; 2.2) | (2.5; 3.7; 4.6) | (1.1; 1.8; 5.7) | (1.2; 3.6; 3.6) | ||
oxLDL/LDL ratio [U/g] | C/C | 52.2 ± 21.3 | 60.7 ± 47.0 | 134.5 ± 113.0 # | 60.3 ± 40.4 ## |
(39.0; 50.8; 63.3) | (27.7; 45.2; 77.3) | (81.4; 97.5; 136.5) | (25.9; 62.5; 94.7) | ||
T/C | 67.6 ± 46.6 | 96.2 ± 64.8 | 117.8 ± 82.4 | 46.2 ± 34.8 | |
(37.1; 50.8; 98.1) | (50.4; 96.2; 142.0) | (64.3; 110.5; 126.9) | (20.4; 45.7; 88.9) | ||
MDA concentration [nmol/µL] | C/C | 0.8 ± 0.6 | 2.4 ± 0.4 * | 2.6 ± 0.6 | 3.1 ± 1.0 # |
(1.7; 2.1; 2.2) | (2.1; 2.4; 2.6) | (2.2; 2.6; 3.0) | (2.5; 3.0; 3.4) | ||
T/C | 0.9 ± 0.9 | 2.0 ± 0.4 * | 2.6 ± 0.5 | 2.8 ± 0.7 | |
(0.2; 0.3; 1.4) | (1.7; 2.1; 2.2) | (2.2; 2.5; 3.2) | (2.1; 3.0; 3.3) |
Healthy Subjects | ||
---|---|---|
Genotypes for SNP rs662 in the PON1 Gene | Correlated Parameters | Correlation Coefficients |
TT | PON1(P) activity–PON1(A) activity | r = 0.6058 p = 0.002 |
PON1(P) activity–PON1(L) activity | r = 0.4195 p = 0.041 | |
PON1(A) activity–PON1(L) activity | r = 0.8219 p < 0.0001 | |
TC | PON1(A) activity–PON1(L) activity | r = 0.9768 p = 0.001 |
Genotypes for SNP −75 bp in the APOA1 gene | Correlated parameters | Correlation coefficients |
GG | PON1(A) activity–PON1(L) activity | r = 0.8265 p < 0.0001 |
AG | PON1(A) activity–PON1(L) activity | r = 0.8353 p = 0.003 |
PON1(P) activity–MDA concentration | r = 0.7638 p = 0.010 | |
AA | PON1(P) activity–MDA concentration | r = 0.99981 p = 0.001 |
Genotypes for SNP +83 bp in the APOA1 gene | Correlated parameters | Correlation coefficients |
CC | PON1(P) activity–PON1(A) activity | r = 0.4840 p = 0.011 |
PON1(A) activity–PON1(L) activity | r = 0.8174 p < 0.0001 | |
PON1(P) activity–MDA concentration | r = 0.4264 p = 0.027 | |
AP patients | ||
Genotypes for SNP rs662 in the PON1 gene | Correlated parameters | Correlation coefficients |
TT | MDA concentration–the value of LDL/HDL ratio | r = 0.9152 p = 0.029 |
TC | PON1(A) activity–PON1(L) activity | r = 0.9999 p = 0.008 |
Genotypes for SNP −75 bp in the APOA1 gene | Correlated parameters | Correlation coefficients |
GG | PON1(A) activity–PON1(L) activity | r = 0.8797 p = 0.021 |
AG | PON1(L) activity–the value of TC/HDL ratio | r = −0.998 p = 0.039 |
AA | PON1(P) activity–PON1(L) activity | r = 0.8432 p = 0.035 |
PON1 concentration–PON1(L) activity | r = 0.9993 p = 0.023 | |
ApoA-I concentration–MDA concentration | r = −0.9842 p = 0.012 | |
Genotypes for SNP +83 bp in the APOA1 gene | Correlated parameters | Correlation coefficients |
CC | PON1(A) activity–PON1(L) activity | r = 0.8772 p = 0.022 |
PON1 concentration–the value of TC/HDL ratio | r = 0.8503 p = 0.032 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ściskalska, M.; Milnerowicz, H. Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein A-I (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis. Genes 2022, 13, 1968. https://doi.org/10.3390/genes13111968
Ściskalska M, Milnerowicz H. Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein A-I (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis. Genes. 2022; 13(11):1968. https://doi.org/10.3390/genes13111968
Chicago/Turabian StyleŚciskalska, Milena, and Halina Milnerowicz. 2022. "Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein A-I (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis" Genes 13, no. 11: 1968. https://doi.org/10.3390/genes13111968
APA StyleŚciskalska, M., & Milnerowicz, H. (2022). Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein A-I (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis. Genes, 13(11), 1968. https://doi.org/10.3390/genes13111968